hrcak mascot   Srce   HID

Izvorni znanstveni članak

Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?

DINKO BAGATIN ; Polyclinic Bagatin, Polyclynic for Maxillofacial, General and Plastic Surgery, Kneza Višeslava 14, 10000 Zagreb, Croatia
KATARINA ŠAKIĆ ; 1_Polyclinic Bagatin, Polyclynic for Maxillofacial, General and Plastic Surgery, Kneza Višeslava 14, 10000 Zagreb, Croatia; 2_Faculty of Medicine University of Osijek, Chair of Anesthesiology, Reanimatology and Intensive Medicine, Osijek, Croatia
TOMICA BAGATIN ; Polyclinic Bagatin, Polyclynic for Maxillofacial, General and Plastic Surgery, Kneza Višeslava 14, 10000 Zagreb, Croatia
DEANA ŠTURM ; Department of Transfusion Medicine and Coagulation in Oncology Patients, Universety Hospital for Tumors, Department of Transfusion Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
MILAN MILOŠEVIĆ ; School of Medicine University of Zagreb, Zagreb, Croatia

Puni tekst: engleski, pdf (1019 KB) str. 291-296 preuzimanja: 386* citiraj
APA 6th Edition
BAGATIN, D., ŠAKIĆ, K., BAGATIN, T., ŠTURM, D. i MILOŠEVIĆ, M. (2015). Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?. Periodicum biologorum, 117 (2), 291-296. Preuzeto s https://hrcak.srce.hr/143051
MLA 8th Edition
BAGATIN, DINKO, et al. "Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?." Periodicum biologorum, vol. 117, br. 2, 2015, str. 291-296. https://hrcak.srce.hr/143051. Citirano 21.02.2020.
Chicago 17th Edition
BAGATIN, DINKO, KATARINA ŠAKIĆ, TOMICA BAGATIN, DEANA ŠTURM i MILAN MILOŠEVIĆ. "Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?." Periodicum biologorum 117, br. 2 (2015): 291-296. https://hrcak.srce.hr/143051
Harvard
BAGATIN, D., et al. (2015). 'Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?', Periodicum biologorum, 117(2), str. 291-296. Preuzeto s: https://hrcak.srce.hr/143051 (Datum pristupa: 21.02.2020.)
Vancouver
BAGATIN D, ŠAKIĆ K, BAGATIN T, ŠTURM D, MILOŠEVIĆ M. Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?. Periodicum biologorum [Internet]. 2015 [pristupljeno 21.02.2020.];117(2):291-296. Dostupno na: https://hrcak.srce.hr/143051
IEEE
D. BAGATIN, K. ŠAKIĆ, T. BAGATIN, D. ŠTURM i M. MILOŠEVIĆ, "Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?", Periodicum biologorum, vol.117, br. 2, str. 291-296, 2015. [Online]. Dostupno na: https://hrcak.srce.hr/143051. [Citirano: 21.02.2020.]

Sažetak
Background and purpose: Breast Cancer is the second most common
cancer among women after skin carcinoma. Incindence in Croatia in 2012 was 2227 new cases per year with mortality 1033 women per year. One of the most pronaunced caracteristics of cancers in general are changes in coagulation factors. Except usual coagulation factors there is thrombelasometry which is dynamic method for evaluation of coagulation factors. We have been used thrombelastometry to see differences in coagulation factors for carcinomas and benign breast diseases.

Materials and methods: We included 132 patients with benign and
malignant breast diseases in Institute of Thumors, Clinical Hospital Center “Sisters of Mersy”, Zagreb, Croatia gathered in prospective study in 2012/2013. We compared differences in coagulation parameters with thrombelastometry and usual coagulation factors in earlier mentioned two groups of patients with Mann-Whitney U test what is graficly described with Box and Whiskers plots and correlatio coefficients are described in table with Spearman correlation coefficients.

Results: A5,A10,A15,A20,A25 and A30, MCF and AUC intem are
significatly higher in malignant breast disease patients. Significant trend of elevation of these values is present in both patients groups, but those are sigificantly higher in patient group with malignant tumors. While in patients group with malignant tumors almost every correlation coefficients between A5-A30, MCF and AUC intem and cogulation markers are significant, those correlations among patients with benign diseases are not significant. Those values suggests that A5-A30, MCF and AUC intem are significatly correlated with most common used coagulation markers only in patients with malignant diseases.

Conclusions: There are differences in coagulation factors in patients
with benign and malignant breast diseases. Trend of elevation of markers of coagulation values is present in both disease, but significantly higher values are in malignant tumor. Our results are based on small numbers and larger number of patients with precise data of coagulation parameters are still needed.

Ključne riječi
breast disease; breast cancer; benign breast disease; coagulation factors; thrombelastometry

Hrčak ID: 143051

URI
https://hrcak.srce.hr/143051

Posjeta: 534 *